Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

Athenex (NASDAQ: ATNX ) stock is falling on Monday after the company announced an agreement with lenders to pursue an expedited sales process. According to a press release from the company, this agreement has it expecting to complete the process by July 1, 2023.

Why Is Athenex (ATNX) Stock Down 54% Today?

To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations  and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company's assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy.

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex's oral paclitaxel plus encequidar in combination with GSK's dostarlimab in the neoadjuvant setting at this year's American Society of Clinical Oncology (ASCO) conference. Athenex, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions collaborated with GSK and Quantum Leap in two study arms of the I-SPY 2 TRIAL.

Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO

Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Athenex (ATNX) Upgraded to Buy: Here's Why

Exploring a range of strategic alternatives

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

MINNETONKA, Minn.--(BUSINESS WIRE)--Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division (APD), has just started to commercialize its abbreviated new drug application (ANDA) approval from the U.S.

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)

BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis.

Athenex Announces a Reverse Stock Split

Ardelyx

Personalis Inc

Use these tips for making money with penny stocks The post A Short Guide to Making Money With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

A Short Guide to Making Money With Penny Stocks in 2023

Boxed

Virios Therapeutics

Penny stocks under $1 to watch this month. The post Penny Stocks To Buy?

Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now

AppHarvest

Blue Apron

Muscle Maker

Grove Collaborative Holdings

IronNet

NeuBase Therapeutics Inc

Pagaya Technologies Ltd

Vislink Technologies Inc

Terawulf

Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 10 Under $1 To Watch This Week

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 6 Under $1 To Watch Now

Avaya Holdings

Icecure Medical Ltd

Use these tips for finding penny stocks to buy in 2022 The post 3 Tips for Identifying Penny Stocks With High Potential appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Identifying Penny Stocks With High Potential

Athenex (NASDAQ: ATNX ) stock is rocketing higher on Tuesday thanks to positive results from a high-risk early-stage breast cancer clinical trial. The Phase 2 study covers the use of the company's oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin.

Why Is Athenex (ATNX) Stock Up 44% Today?

Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroup Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroup

Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Full-year 2022 product sales guidance maintained at 20-25% growth year-over-year Full-year 2022 product sales guidance maintained at 20-25% growth year-over-year

Athenex Exits 503B Sterile Compounding Business

BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special meeting of stockholders (the “Special Meeting”), held as a virtual meeting on November 22, 2022.

Athenex Announces Positive Results of Special Stockholder Meeting

BUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its equity interests in its China subsidiaries, which primarily represent the Company's ownership of its active pharmaceutical ingredient (API) manufacturing business in China, to Chongqing Comfort Pharmaceutical Inc. (Chongqing Comfort). Chongqing Comfort was assigned the rights and obligations under the Equity Purchase Agreement (Agreement) entered into in July 2022 by TiHe Capital (Beijing) Co. Ltd, pursuant to the terms of the Agreement.

Athenex Announces Closing of the Sale of its China API Business

Athenex, Inc. (NASDAQ:ATNX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Tim McCarthy - MD, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical Officer, Cell Therapy Jeff Yordon - Chief Operating Officer Joe Annoni - Chief Financial Officer Conference Call Participants Jon Miller - Evercore Yale Jen - Laidlaw & Co Operator Good day, ladies and gentlemen and welcome to the Athenex Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Tim McCarthy, Managing Director of Investor Relations at LifeSci Advisors.

Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2022 Results - Earnings Call Transcript

Athenex (ATNX) delivered earnings and revenue surprises of 12.50% and 16.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates

Nasdaq Hearing Panel grants continued listing of Athenex and extension to regain compliance with the minimum bid price requirement Nasdaq Hearing Panel grants continued listing of Athenex and extension to regain compliance with the minimum bid price requirement

Athenex Announces Receipt of Positive Nasdaq Listing Determination

BUFFALO, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the third quarter ended September 30, 2022.

Athenex Provides Third Quarter 2022 Financial Results and Business Update

BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.

Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

BUFFALO, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission in connection with a special meeting of stockholders (the "Special Meeting") scheduled on November 22, 2022 (to be held virtually as a live webcast). The Special Meeting is being held to vote on three matters, including to effect an increase in the total number of authorized shares of common stock of the Company, to effect a reverse stock split of the issued and outstanding shares of common stock, and to increase the number of shares available for issuance under the Company's 2017 Omnibus Incentive Plan. The Company's board of directors has recommended that stockholders vote their shares “FOR” each of the proposals presented at the Special Meeting.

Athenex Files Definitive Proxy Statement for Special Stockholder Meeting

BUFFALO, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) --  Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY and virtually. Company management will also be available for one-on-one investor meetings during the event. Please find additional details about the presentation below.

Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of its underwritten public offering of 35,333,334 shares of its common stock and accompanying warrants to purchase up to 35,333,334 shares of common stock at a combined public offering price of $0.75 per share and accompanying warrant and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 4,666,666 shares of its common stock and accompanying warrants to purchase up to 4,666,666 shares of common stock at a combined public offering price of $0.749 per share and accompanying warrant . The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately, and will expire five years following the date of issuance. The warrants have an exercise price of $1.00 per share, are exercisable immediately, and will expire five years following the date of issuance. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and offering expenses, are expected to be approximately $30 million. The offering is expected to close on August 15, 2022, subject to customary closing conditions.

News for Athenex Stock (ATNX)